Publikation:

Human lung carcinomas express Fas ligand

Lade...
Vorschaubild

Dateien

1997_Niehans_Human Lung Carci.pdf
1997_Niehans_Human Lung Carci.pdfGröße: 2.59 MBDownloads: 185

Datum

1997

Autor:innen

Niehans, Gloria A.
Brunner, Thomas
Frizelle, Sandra P.
Liston, Jacob C.
Salerno, Christopher T.
Knapp, Dennis J.
Green, Douglas R.
Kratzke, Robert A.

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

DOI (zitierfähiger Link)
ArXiv-ID

Internationale Patentnummer

Angaben zur Forschungsförderung

Projekt

Open Access-Veröffentlichung
Open Access Green
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Cancer Research. 1997, 57(6), pp. 1007-1012

Zusammenfassung

To reach a clinically detectable size, neoplasms must be able to suppress or evade a host immune response. Activated T cells may enter apoptosis in the presence of Fas ligand (FasL) (1), and tissue expression of FasL has been shown to contribute to immune privilege in the eye and testis (2, 3). We have demonstrated that all human lung carcinoma cell lines tested (16 of 16) express a Mr 38,000 protein consistent with FasL by immunoblotting, whereas the majority of resected tumors (23 of 28) show positive staining for FasL by immunohistochemistry. DNA sequencing of reverse transcription-PCR products from lung cancer cells and resected lung tumors confirms the presence of human FasL mRNA in these neoplastic tissues. Furthermore, lung carcinoma cells are capable of killing a Fassensitive human T cell line (Jurkat) in coculture experiments; this killing was inhibited by a recombinant form of the soluble portion of the Fas receptor (FasFc). FasL expression by neoplastic cells represents a potential mechanism for peripheral deletion of tumor-reactive T-cell clones.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
570 Biowissenschaften, Biologie

Schlagwörter

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690NIEHANS, Gloria A., Thomas BRUNNER, Sandra P. FRIZELLE, Jacob C. LISTON, Christopher T. SALERNO, Dennis J. KNAPP, Douglas R. GREEN, Robert A. KRATZKE, 1997. Human lung carcinomas express Fas ligand. In: Cancer Research. 1997, 57(6), pp. 1007-1012
BibTex
@article{Niehans1997Human-14312,
  year={1997},
  title={Human lung carcinomas express Fas ligand},
  number={6},
  volume={57},
  journal={Cancer Research},
  pages={1007--1012},
  author={Niehans, Gloria A. and Brunner, Thomas and Frizelle, Sandra P. and Liston, Jacob C. and Salerno, Christopher T. and Knapp, Dennis J. and Green, Douglas R. and Kratzke, Robert A.}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/14312">
    <dc:creator>Liston, Jacob C.</dc:creator>
    <dc:contributor>Salerno, Christopher T.</dc:contributor>
    <dc:creator>Frizelle, Sandra P.</dc:creator>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-07-29T09:06:42Z</dcterms:available>
    <dc:rights>terms-of-use</dc:rights>
    <dc:contributor>Frizelle, Sandra P.</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-07-29T09:06:42Z</dc:date>
    <dc:contributor>Knapp, Dennis J.</dc:contributor>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/14312"/>
    <dc:creator>Salerno, Christopher T.</dc:creator>
    <dc:creator>Green, Douglas R.</dc:creator>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Brunner, Thomas</dc:creator>
    <dc:contributor>Green, Douglas R.</dc:contributor>
    <dc:contributor>Niehans, Gloria A.</dc:contributor>
    <dc:contributor>Liston, Jacob C.</dc:contributor>
    <dc:creator>Niehans, Gloria A.</dc:creator>
    <dc:contributor>Brunner, Thomas</dc:contributor>
    <dc:language>eng</dc:language>
    <dcterms:title>Human lung carcinomas express Fas ligand</dcterms:title>
    <dcterms:abstract xml:lang="eng">To reach a clinically detectable size, neoplasms must be able to suppress or evade a host immune response. Activated T cells may enter apoptosis in the presence of Fas ligand (FasL) (1), and tissue expression of FasL has been shown to contribute to immune privilege in the eye and testis (2, 3). We have demonstrated that all human lung carcinoma cell lines tested (16 of 16) express a Mr 38,000 protein consistent with FasL by immunoblotting, whereas the majority of resected tumors (23 of 28) show positive staining for FasL by immunohistochemistry. DNA sequencing of reverse transcription-PCR products from lung cancer cells and resected lung tumors confirms the presence of human FasL mRNA in these neoplastic tissues. Furthermore, lung carcinoma cells are capable of killing a Fassensitive human T cell line (Jurkat) in coculture experiments; this killing was inhibited by a recombinant form of the soluble portion of the Fas receptor (FasFc). FasL expression by neoplastic cells represents a potential mechanism for peripheral deletion of tumor-reactive T-cell clones.</dcterms:abstract>
    <dc:creator>Kratzke, Robert A.</dc:creator>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/14312/2/1997_Niehans_Human%20Lung%20Carci.pdf"/>
    <dc:creator>Knapp, Dennis J.</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:issued>1997</dcterms:issued>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/14312/2/1997_Niehans_Human%20Lung%20Carci.pdf"/>
    <dc:contributor>Kratzke, Robert A.</dc:contributor>
    <dcterms:bibliographicCitation>First publ. in: Cancer Research ; 57 (1997), 6. - pp. 1007-1012</dcterms:bibliographicCitation>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Nein
Begutachtet
Diese Publikation teilen